BriaCell reports median OS of 15.6 months in Phase 2 Bria-IMT study; FDA path cleared for Bria-PROS+

BriaCell Therapeutics Corp.

Median overall survival of 15.6 months in 25 patients receiving Phase 3 Bria-IMT formulation vs 6.7–9.3 months in literature controls.
FDA Pre-IND meeting gave positive feedback; waived animal toxicology/PK studies for Bria-PROS+ prostate cancer trial.
No drug-related discontinuations reported in the Phase 2 study; ongoing Phase 3 pivotal study NCT06072612.
Poster presentation at SITC 2024 (Nov 8, Houston) on novel targeted immunotherapy candidates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.